Message #5 From:
Stock News Bot Date: May 3, 2005 09:57:09 AM
IAGX Jason Theodosakis and Lorna Vanderhaeghe Join Imagenetix's Scientific and Medical Advisory Board
Jason Theodosakis and Lorna Vanderhaeghe Join Imagenetix's Scientific and Medical Advisory Board
SAN DIEGO
Imagenetix, Inc.
Patrick Millsap, 858-674-8455
Imagenetix, Inc. (OTCBB: IAGX), www.imagenetix.net, an innovator of scientifically tested, natural-based, proprietary bioceutical products that enhance human health, announced today the addition of two new members to the Imagenetix Scientific and Medical Advisory Board.
Bill Spencer, CEO of Imagenetix, said, "It gives me great pleasure to welcome Dr. Jason Theodosakis and Lorna Vanderhaeghe, two highly regarded authors and internationally acclaimed medical and health professionals to the Imagenetix Scientific and Medical Advisory Board."
Jason Theodosakis ("Dr. Theo"), MD, MS, MPH, FACPM, is considered to be one of the world's foremost authorities on osteoarthritis treatment and is perhaps the most quoted doctor in the world regarding the use of glucosamine and chondroitin supplements. Dr. Theo is a practicing physician, board-certified in the specialty of Preventive Medicine, and had the distinction of being named to the oversight steering committee of the NIH's study on glucosamine/chondroitin. His undergraduate education includes a double major in Chemistry and Biology. Dr. Theo graduated summa cum laude from his advanced studies with master's in both Exercise Physiology and in Public Health. His medical degree is from the University of Health Sciences/Chicago Medical School.
An accomplished author, Dr. Theo's first book, The Arthritis Cure, became an international #1 best-seller and resulted in a major paradigm shift in the way arthritis and other chronic diseases are treated. Dr. Theo spends much of his time lecturing and speaking with the media. He has been a guest on The Today Show, Prime Time Live, NBC and CBS Evening and Morning News, CNN, Fox Network News and many others. In addition, he has been featured in print in such publications as Time, Newsweek, US News & World Report, People, USA Today, The NY Times, Parade, People, Reader's Digest, Prevention, and other magazines. He speaks often on local and national radio, and he is a frequent lecturer at medical conventions and forums throughout the country.
In addition to providing input for clinical design, Dr. Theo will assist the company in the future direction of Imagenetix's Celadrin products.
Ms. Lorna R. Vanderhaeghe ("Lorna") is a best-selling author and medical journalist who has been researching and writing on nutritional subject matter for the past 20 years. Lorna received her B.Sc. degree in Bio-Chemistry from Simon Fraser University located in Canada.
Lorna is an associate editor for Total Health Magazine and is an author and a co-author of a number of health books including The Immune System Cure published in six countries and translated into French, Dutch, and German, and she is author of the Canadian bestseller Healthy Immunity: Scientifically Proven Natural Treatments for Conditions from A-Z. Lorna's most recent book, Get a Grip On Arthritis: and Other Inflammatory Disorders was published and released in November of 2004.
An accomplished communicator, Lorna speaks as many as 300 times per year throughout the North American continent on television, radio, conventions, and through the print media.
Her input into newsworthy clinical studies will be of great value to Imagenetix. Lorna has also become a spokesperson for Imagenetix's Celadrin products.
About Celadrin(R)
Celadrin(R) is a natural compound composed of esterified fatty acid carbons (EFACs) and other active synergists, and is a proprietary Imagenetix product. Celadrin(R) can be formulated into both pill and cream forms and it can be used in formulations with other compounds to address the $22 billion joint health market. Celadrin(R) is currently available in oral form as a dietary supplement and as an over-the-counter topical cream at food, drug and mass retail stores.
In a double-blind, multi-center, placebo-controlled clinical trial of Celadrin(R), researchers examined the impact of an oral administration of Celadrin(R) on participants who were experiencing joint and mobility challenges of the knee. The placebo group and the Celadrin(R) group were evaluated at baseline, at 30 days, and at 68 days. Data from the study indicated that Celadrin(R) not only promoted joint flexibility, but also supported and promoted the ability to walk long distances.(1)
In an age-matched, double-blind study of patients diagnosed with osteoarthritis of the knee, researchers examined the impact of a topical administration of Celadrin(R) on participants. The placebo group and the Celadrin(R) group were evaluated at baseline, 30 minutes following initial treatment, and after 30 days, having applied the cream twice per day. Study data revealed that 100% of the participants using the Celadrin(R) cream experienced significant improvement in their ability to ascend and descend stairs, exhibit greater range of motion of the knee, ease of rising from a chair, functional mobility, and improved quality of life.(1) A most unique finding was that participants using the Celadrin(R) cream experienced an immediate effect from the treatment 30 minutes following the initial application.
(1) These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
About Imagenetix, Inc.
San Diego-based Imagenetix, Inc. (OTCBB: IAGX), www.imagenetix.net, is an innovator of scientifically tested, natural-based, proprietary bioceutical products that enhance human health. The Company develops, formulates and private-labels, proprietary, leading edge over-the-counter topical creams, skin care products and nutritional supplements to be marketed globally through multiple channels of distribution. Imagenetix also develops and formulates proprietary patentable pharmaceutical products.
Safe Harbor Statement
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.
